TVTX
Travere Therapeutics Inc
$
18.230
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
18.430
Open
17.940
VWAP
18.16
Vol
1.54M
Mkt Cap
1.62B
Low
17.840
Amount
27.91M
EV/EBITDA(TTM)
--
Total Shares
76.13M
EV
1.67B
EV/OCF(TTM)
--
P/S(TTM)
4.57
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
107.19M
+70.42%
-0.047
-89.75%
120.05M
+60.52%
0.061
-113.07%
117.48M
+43.74%
-0.040
-78.95%
Estimates Revision
The market is revising Upward the revenue expectations for Travere Therapeutics, Inc. (TVTX) for FY2025, with the revenue forecasts being adjusted by 1.23% over the past three months. During the same period, the stock price has changed by -13.56%.
Revenue Estimates for FY2025
Revise Upward
+1.23%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-13.56%
In Past 3 Month
14 Analyst Rating
82.28% Upside
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 33.23 USD with a low forecast of 23.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy
82.28% Upside
Current: 18.230
Low
23.00
Averages
33.23
High
47.00
82.28% Upside
Current: 18.230
Low
23.00
Averages
33.23
High
47.00
Citi
Buy
upgrade
$32 -> $34
2025-08-10
New
Reason
Citi
Price Target
$32 -> $34
2025-08-10
New
upgrade
Buy
Reason
Citi raised the firm's price target on Travere Therapeutics to $34 from $32 and keeps a Buy rating on the shares. The firm sees meaningful potential upside for the shares with two near-term FDA action dates for Travere. Citi upped the company's estimates to reflect continued demand growth for Filspari in immunoglobulin A nephropathy.
Wedbush
Outperform
maintain
$30 -> $32
2025-08-07
Reason
Wedbush
Price Target
$30 -> $32
2025-08-07
maintain
Outperform
Reason
Wedbush raised the firm's price target on Travere Therapeutics to $32 from $30 and keeps an Outperform rating on the shares. The firm notes Q2 update represented another strong showing for Filspari with Travere reporting a Filspari beat. With PSFs continuing to show growth, Wedbush thinks this bodes well for the forward revenue trajectory.
Scotiabank
Outperform
maintain
$30 -> $31
2025-08-07
Reason
Scotiabank
Price Target
$30 -> $31
2025-08-07
maintain
Outperform
Reason
Scotiabank raised the firm's price target on Travere Therapeutics to $31 from $30 and keeps an Outperform rating on the shares. The company reported "impressive" results for Fislapri in IgA nephropathy, IgAN, in Q2, and the firm believes there are numerous reasons why this outperformance can continue, the analyst tells investors.
Citi
Buy
maintain
$35 -> $32
2025-06-11
Reason
Citi
Price Target
$35 -> $32
2025-06-11
maintain
Buy
Reason
Citi lowered the firm's price target on Travere Therapeutics to $32 from $35 and keeps a Buy rating on the shares. The firm also added an "upside 90-day catalyst watch" on the shares. Citi updated its model post the Q1 report. It expects Travere to receive FDA approval on or before the upcoming FDA action date of August 28 for the applicating seeking a lighter Risk Evaluation and Mitigation Strategies program for Filspari for the treatment of immunoglobulin A nephropathy. The potential modifications include a step-down in liver monitoring from monthly to quarterly, and in a best-case scenario the REMS could be lifted entirely, the analyst tells investors in a research note. The firm expects increased and accelerated uptake in IgAN assuming approval of the application.
H.C. Wainwright
Buy
initiated
$30
2025-06-11
Reason
H.C. Wainwright
Price Target
$30
2025-06-11
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Travere Therapeutics with a Buy rating and $30 price target. The primary focus is the Filspari commercial launch in the U.S., which is now the only fully approved, non-immunosuppressing, kidney-targeted therapy positioned to potentially replace standard of care, the analyst tells investors in a research note. The firm says Filspari looks to leverage a key opportunity to move into earlier lines of therapy for IgAN.
Citi
Yigal Nochomovitz
Buy
maintain
$35
2025-05-16
Reason
Citi
Yigal Nochomovitz
Price Target
$35
2025-05-16
maintain
Buy
Reason
Citi analyst Yigal Nochomovitz would be buying the selloff in Travere Therapeutics on news the company received standard versus the anticipated priority review timeframe for sparsentan in focal segmental glomerulosclerosis. The firm says the four month clock to organize, prepare for and hold an advisory committee meeting and then reach an approval determination "was too tight" in light of possible workload balance/constraints at an evolving FDA. Citi believes the standard review timeline does not change conviction on the conclusions from the PARASOL working group supporting proteinurea as an approvable endpoint in FSGS. It keeps a Buy rating on Travere with a $35 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Travere Therapeutics Inc (TVTX.O) is 235.27, compared to its 5-year average forward P/E of 3.12. For a more detailed relative valuation and DCF analysis to assess Travere Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
3.12
Current PE
235.27
Overvalued PE
73.14
Undervalued PE
-66.90
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
12.14
Current EV/EBITDA
17.69
Overvalued EV/EBITDA
90.52
Undervalued EV/EBITDA
-66.25
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
5.39
Current PS
3.24
Overvalued PS
7.34
Undervalued PS
3.44
Financials
Annual
Quarterly
FY2025Q2
YoY :
+111.49%
114.45M
Total Revenue
FY2025Q2
YoY :
-81.13%
-12.65M
Operating Profit
FY2025Q2
YoY :
-81.69%
-12.76M
Net Income after Tax
FY2025Q2
YoY :
-84.62%
-0.14
EPS - Diluted
FY2025Q2
YoY :
-93.72%
-7.34M
Free Cash Flow
FY2025Q2
YoY :
+2.58%
98.67
Gross Profit Margin - %
FY2025Q2
YoY :
-81.31%
-45.01
FCF Margin - %
FY2025Q2
YoY :
-91.34%
-11.14
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
11.9K
USD
1
3-6
Months
644.7K
USD
6
6-9
Months
5.1M
USD
26
0-12
Months
1.8M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
300.0K
Volume
1
6-9
Months
859.2K
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
5
4.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
11.9K
USD
1
3-6
Months
644.7K
USD
6
6-9
Months
5.1M
USD
26
0-12
Months
1.8M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TVTX News & Events
Events Timeline
2025-05-15 (ET)
2025-05-15
16:14:52
Travere Therapeutics announces FDA acceptance of sNDA for Filspari
2025-05-01 (ET)
2025-05-01
16:42:10
Travere Therapeutics reports Q1 adjusted EPS (19c), consensus (39c)
2025-04-29 (ET)
2025-04-29
07:51:33
Travere, CSL Vifor report EC approval of Filspari for IgA nephropathy
Sign Up For More Events
Sign Up For More Events
News
8.0
08-13NASDAQ.COMNotable Wednesday Option Activity: TVTX, EL, SMR
4.0
08-07BenzingaWedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $32
1.0
08-05NewsfilterTravere Therapeutics to Participate at Upcoming Investor Conferences
Sign Up For More News
People Also Watch
CSTM
Constellium SE
14.080
USD
-1.12%
TROX
Tronox Holdings PLC
3.760
USD
+0.53%
VET
Vermilion Energy Inc
7.320
USD
-0.14%
DMLP
Dorchester Minerals LP
25.050
USD
+1.25%
MAG
MAG Silver Corp
22.850
USD
-0.57%
CUBI
Customers Bancorp Inc
66.660
USD
+1.15%
NCTY
The9 Ltd
8.180
USD
-1.09%
GLPG
Galapagos NV
31.790
USD
-1.58%
TDOC
Teladoc Health Inc
7.300
USD
-1.88%
FAQ
What is Travere Therapeutics Inc (TVTX) stock price today?
The current price of TVTX is 18.23 USD — it has increased 1 % in the last trading day.
What is Travere Therapeutics Inc (TVTX)'s business?
What is the price predicton of TVTX Stock?
What is Travere Therapeutics Inc (TVTX)'s revenue for the last quarter?
What is Travere Therapeutics Inc (TVTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Travere Therapeutics Inc (TVTX)'s fundamentals?
How many employees does Travere Therapeutics Inc (TVTX). have?